Related Experiment Video

Updated: Jun 15, 2025

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
09:12

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

15.8K

Antagonism of β-arrestins in IL-4-driven microglia reactivity via the Samd4/mTOR/OXPHOS axis in Parkinson's disease

Jiaqi Liu1, Yue Liang1, Qinghao Meng1

  • 1Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, School of Basic Medical Sciences, Nanjing Medical University, 818 Tianyuan East Road, Nanjing, Jiangsu 211166, China.

Science Advances
|August 21, 2024
PubMed

Insights

Interleukin-4 (IL-4) boosts microglia

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Microglia, the immune cells of the brain, play a crucial role in neuroinflammation.
  • Interleukin-4 (IL-4) exposure can induce neuroprotective properties in microglia.
  • The precise role and regulation of IL-4-modulated microglia in Parkinson's disease (PD) remain unclear.

Purpose of the Study:

  • To investigate how IL-4 affects microglia in Parkinson's disease (PD) mouse models.
  • To explore the involvement of β-arrestin 1 and β-arrestin 2 in IL-4-induced microglia functions.
  • To elucidate the molecular pathways regulating these interactions.

Main Methods:

  • Utilized PD mouse models and in vitro cell cultures.
  • Administered IL-4 to microglia and analyzed changes in their reactivity and expression of β-arrestins.
  • Investigated the downstream signaling pathways involving sterile alpha motif domain containing 4 (Samd4), mammalian target of rapamycin (mTOR), and mitochondrial oxidative phosphorylation (OXPHOS).

Main Results:

  • IL-4 enhanced anti-inflammatory microglia responses and reduced PD pathology in mouse models.
  • IL-4 modulated the expression of β-arrestin 1 and β-arrestin 2 in microglia.
  • Manipulating β-arrestins demonstrated opposing effects on IL-4-induced microglia functions.
  • The functional antagonism between β-arrestins was mediated by the Samd4/mTOR/OXPHOS pathway.

Conclusions:

  • β-arrestin 1 and β-arrestin 2 exhibit opposing roles in regulating IL-4-induced microglia reactivity in PD.
  • The Samd4/mTOR/OXPHOS axis is a key pathway in this regulation.
  • These findings offer novel insights into PD pathogenesis and potential therapeutic strategies targeting microglia.

More Related Videos

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.5K
Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility07:54

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility

Published on: April 13, 2017

9.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
500